貸借対照表 2023 年 8 月 31 日 Chordia Therapeutics 株式会社 Balance Sheet As of august 31,2023

(単位/Unit:千円/Thousand yen)

| 資産の部                     | ASSETS                               | t :     1/ 1/ Housand yell) |  |  |  |  |
|--------------------------|--------------------------------------|-----------------------------|--|--|--|--|
| 流動資産                     | E Current assets                     |                             |  |  |  |  |
| 現金及び預金                   | Cash and deposits                    | 4,799,035                   |  |  |  |  |
| 前渡金                      | Advance payments - trade             | 40,518                      |  |  |  |  |
| 前払費用                     | Prepaid expenses                     | 52,058                      |  |  |  |  |
|                          |                                      |                             |  |  |  |  |
| 流動資産合計                   | Current Assets Total                 | 4,891,612                   |  |  |  |  |
| 固定資産                     | Non-Current assets                   |                             |  |  |  |  |
| 有形固定資産                   | Tangible Assets                      |                             |  |  |  |  |
| 工具、器具備品                  | Tools, furniture and fixtures        | 10,675                      |  |  |  |  |
| 減価償却累計額                  | Accumulated Depreciation             | -6,249                      |  |  |  |  |
| 有形固定資産合計                 | Tangible Fixed Assets Total          | 4,425                       |  |  |  |  |
| 無形固定資産                   | Intangible Assets                    |                             |  |  |  |  |
| ソフトウェア                   | Software                             | 2,497                       |  |  |  |  |
| 無形固定資産合計                 | Intangible Assets Total              | 2,497                       |  |  |  |  |
| 投資その他の資産                 | Investments and other Assets         |                             |  |  |  |  |
| 長期前払費用                   | Long-term prepaid expenses           | 8,691                       |  |  |  |  |
| その他                      | Investments and other assets - other | 1,894                       |  |  |  |  |
| 投資その他の資産合計               | Investments and other Assets Total   | 10,586                      |  |  |  |  |
| 固定資産合計                   | Non-Current Assets Total             | 17,510                      |  |  |  |  |
| 資産の部合計 ASS               | SETS TOTAL                           | 4,909,123                   |  |  |  |  |
| 負債の部                     | LIABILITIES                          |                             |  |  |  |  |
| 流動負債 Current liabilities |                                      |                             |  |  |  |  |
| 未払金                      | Accounts payable-other               | 248,433                     |  |  |  |  |
| 賞与引当金                    | Allowance for Bonuses                | 15,720                      |  |  |  |  |
| 未払費用                     | Accrued expenses                     | 9,882                       |  |  |  |  |
| 未払法人税等                   | Income taxes payable                 | 2,420                       |  |  |  |  |
| その他                      | Current liabilities – other          | 131,784                     |  |  |  |  |
| 流動負債合計                   | Current Liabilities Total            | 408,241                     |  |  |  |  |
| 負債の部合計 LIA               | ABILITIES TOTAL                      | 408,241                     |  |  |  |  |
| 純資産の部                    | NET ASSETS                           |                             |  |  |  |  |
| 株主資本                     | Shareholder's Equity                 |                             |  |  |  |  |
| 資本金                      | Capital Stock                        | 90,000                      |  |  |  |  |
| 資本準備金                    | Legal capital surplus                | 5,406,936                   |  |  |  |  |
| その他資本剰余金                 | Other capital surplus                | 2,872,664                   |  |  |  |  |
| 資本剰余金合計                  | Capital Surplus                      | 8,279,601                   |  |  |  |  |
| その他利益剰余金                 | Other retained earnings              |                             |  |  |  |  |
| <u> </u>                 |                                      |                             |  |  |  |  |

| 繰越利益剰余金   | Retained Earnings                   | -3,894,652 |
|-----------|-------------------------------------|------------|
| 利益剰余金合計   | Earned Surplus                      | -3,894,652 |
| 株主資本合計    | Shareholder's Equity Total          | 4,474,948  |
| 新株子       | · 約権 Share acquisition rights       | 25,933     |
| 純資産の部合計   | NET ASSETS TOTAL                    | 4,500,881  |
| 負債及び純資産の部 | 合計 LIABILITIES AND NET ASSETS TOTAL | 4,909,123  |

当期純利益は、223,341 千円です。

Net Income for the period was 223,341 thousand yen.

重要な会計方針に係る事項に関する注記

Notes to important matters concerning accounting policy

- 1. 固定資産の減価償却の方法 Method of depreciation for fixed assets
  - (1) 有形固定資産:定率法を採用しております。

Tangible Assets: Depreciation is calculated on a declining-balance basis

主な耐用年数は以下のとおりであります。

The main useful lives are as follows.

工具、器具及び備品: 3~5年

Tools, furniture, and fixtures: 3~5 years

(2) 無形固定資産:定額法を採用しております。

Intangible Assets: Depreciation is calculated on a straight-line basis

自社利用のソフトウェアについては、社内における利用可能期間 (3年) に基づいております。

Software for internal use is amortized over the estimated useful life (3 years).

2. 繰延資産の会計処理 Accounting processing for deferred assets

株式交付費 Share issuance cost

支出時に全額費用処理しております。

The entire amount is expensed at the time of payment.

3. 外貨建ての資産及び負債の本邦追加への換算基準

Translation of assets and liabilities denominated in foreign currencies into Japanese yen 外貨建金銭債権債務は、期末日の直物為替相場により円貨に換算し、換算差額は損益として処理しております。

Monetary receivables and payables denominated in foreign currencies are translated into yen at the spot exchange rates prevailing at the balance sheet date.

#### 4. 引当金の計上基準 Basis for calculating the provision

賞与引当金 Allowance for Bonuses

従業員に対して支給する賞与の支出に備えるため、賞与支給見込額のうち当事業年 度の 負担額を計上しております。

To provide for payment of bonuses to employees, the Company accrues an estimated amounts of bonuses to be paid in the current fiscal year.

#### 5. 収益及び費用の計上基準 Accounting processing for income and expenses

当社は、医薬品の研究開発を行っており、ライセンス契約等に基づく契約一時金及びマイルストン収入を得ております。契約一時金は、履行義務が一時点で充足される場合にはライセンスを付与した時点で収益を認識しており、マイルストン収入は、事後に重大な戻入れが生じる可能性を考慮し、契約上定められたマイルストンが達成された時点で収益を認識することとしております。

なお、当社が認識した収益に係る対価は、通常、履行義務の充足から1年以内に受領しており、重大な金融要素は含まれておりません。

The Company conducts research and development of pharmaceutical products and receives upfront and milestone revenues under license agreements and other contracts. Upfront payments are recognized at the time the license is granted if the performance obligation is satisfied at a point in time, and milestone revenues are recognized when the contractually stipulated milestone is achieved, taking into account the possibility of significant reversals later.

The consideration for the revenue recognized by the Company is generally received within one year of satisfaction of the performance obligation and does not include a significant financial component.

# 税効果会計に関する注記

# Notes to tax effect accounting

繰延税金資産及び繰延税金負債の発生の主な原因別の内訳

# Summary of deferred tax assets and liabilities

繰延税金資産 deferred tax assets

| 税務上の繰越欠損金 tax loss carryforwards              | 1,127,086 千円 |  |  |  |
|---|--------------|--|--|--|
| 賞与引当金 provision for bonuses                   | 5,345        |  |  |  |
| 棚卸資産 inventories                              | 170,196      |  |  |  |
| 減価償却超過額 excess depreciation                   | 3,233        |  |  |  |
| 株式報酬費用 share-based payment expenses           | 7,820        |  |  |  |
| その他 other                                     | 3,408        |  |  |  |
| 繰延税金資産小計 subtotal of deferred tax assets      | 1,317,091    |  |  |  |
| 税務上の繰越欠損金に係る評価性引当額                            | -1,127,086   |  |  |  |
| valuation allowance of tax loss carryforwards | 1,127,000    |  |  |  |
| 将来減算一時差異等の合計に係る評価性引当額                         | -190,004     |  |  |  |
| other valuation allowance                     |              |  |  |  |
| 評価性引当額小計 subtotal of valuation allowance      | -1,317,091   |  |  |  |
| 繰延税金資産合計 deferred tax assets total            | _            |  |  |  |
| 繰延税金負債 deferred tax liabilities               |              |  |  |  |
| その他 other                                     | _            |  |  |  |
| 繰延税金負債合計 deferred tax liabilities total       | _            |  |  |  |
| 繰延税金資産(負債)の純額 net deferred tax assets         | _            |  |  |  |

#### Notes to related parties

親会社及び主要株主等

Parent company and major shareholders, etc.

| 種類<br>Category                   | 会社等の<br>名称又は<br>氏名<br>Name of<br>Company,<br>etc.                         | 所在地<br>Location  | 資本金<br>又は出<br>資金<br>(百万<br>円)<br>Capital<br>or<br>investme<br>nts in<br>capital<br>(Millions<br>of yen) | 事業の<br>内容又<br>は職業<br>Descripti<br>on of<br>business<br>or<br>occupati<br>on   | 議決権等<br>の所有<br>(被所有)割合<br>(%)<br>Voting<br>rights<br>ownership<br>(owned)<br>ratio (%) | 関連当事<br>者との関<br>係<br>Relations<br>hip with<br>related<br>parties                             | 取引の内<br>容<br>Transaction<br>details  | 取引金額<br>(千円)<br>Transaction<br>amount<br>(Thousands<br>of yen) | 科目<br>Title | 期末残高<br>(千円)<br>Ending<br>balancer<br>(Thousands<br>of yen) |
|----------------------------------|---|--|---|---|--|--|--|--|-------------|---|
| 主要株主<br>Major<br>Sharehold<br>er | 武田薬品<br>工業株式<br>会社<br>Takeda<br>Pharmace<br>utical<br>Company<br>Limited. | 大阪府<br>大阪市<br>中央区<br>道修町<br>Doshoma<br>chi,<br>Chuo-ku,<br>Osaka-<br>shi,<br>Osaka | 1,676,345   | 医薬品等の開発・射機・大きの開発・・輸出入 Research and develop ment, manufac ture, sale, import and export of pharmac euticals and other products | (被所<br>有)直接<br>16.7<br>(being<br>owned)<br>direct<br>16.7                              | 医薬品等<br>の共同研<br>究<br>Joint<br>research<br>on<br>pharmace<br>uticals<br>and other<br>products | 転籍従業<br>員に対す<br>る給与サポート等<br>Payroll<br>support<br>for<br>transferre<br>d<br>employee<br>s, etc | 17,204   |             |   |

<sup>(</sup>注) 取引条件及び取引条件の決定方針等

(Note) Terms and conditions of transactions and policy for determining terms and conditions of transactions, etc.

武田薬品工業株式会社との間で協議のうえ締結した契約書に基づき、取引条件を決定しています。

The terms and conditions of the transaction are determined based on the agreement concluded after discussion with Takeda Pharmaceutical Company Limited.

### 1株当たり情報に関する注記

Notes to per share information

1株当たりの純資産額 Net assets per share 79.28 円 79.28 yen

1株当たりの当期純利益 Net income per share 3.96 円 3.96yen

重要な後発事象に関する注記

Notes to Significant Subsequent Events

該当事項はありません。

Not applicable.